AstraZeneca's Multi-Tumor Opportunity Still Exists By: Benzinga via Benzinga May 18, 2016 at 13:43 PM EDT AstraZeneca plc (ADR) (NYSE: AZN) announced that Lynparza, which has already received approval for ovarian cancer, failed to meet the ... Read More >> Related Stocks: Astrazeneca Plc ADR